Evidence map›Paper›PMID 33907298›Full record

SynthesisScientific reports2021

Therapeutic effects of micro-RNAs in preclinical studies of acute kidney injury: a systematic review and meta-analysis.

Sarah Zankar, Mayra Trentin-Sonoda, Jose L Viñas, Rosendo A Rodriguez, Adrian Bailey, David Allan, Kevin D Burns

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Nephroprotective effects ofAnnals of medicine and surgery (2012) · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sarah ZankarDepartment of Medicine, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
Mayra Trentin-SonodaDivision of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 1967 Riverside Drive, Rm. 535, Ottawa, ON, K1H 7W9, Canada.
Jose L ViñasDivision of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 1967 Riverside Drive, Rm. 535, Ottawa, ON, K1H 7W9, Canada.
Rosendo A RodriguezDepartment of Medicine, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
Adrian BaileyDepartment of Medicine, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
David AllanDepartment of Medicine, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
Kevin D BurnsDivision of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 1967 Riverside Drive, Rm. 535, Ottawa, ON, K1H 7W9, Canada. kburns@toh.ca.ORCID 0000-0002-1482-5826
University of Ottawa · CA

Funding

CIHR 388364
6 · The paper itself

Abstract

AKI has a high mortality rate, may lead to chronic kidney disease, and effective therapies are lacking. Micro-RNAs (miRNAs) regulate biologic processes by potently inhibiting protein expression, and pre-clinical studies have explored their roles in AKI. We conducted a systematic review and meta-analysis of miRNAs as therapeutics in pre-clinical AKI. Study screening, data extraction, and quality assessments were performed by 2 independent reviewers. Seventy studies involving 42 miRNA species were included in the analysis. All studies demonstrated significant effects of the miRNA intervention on kidney function and/or histology, with most implicating apoptosis and phosphatase and tensin homolog (PTEN) signaling. Fourteen studies (20.0%) examined the effect of miRNA-21 in AKI, and meta-analysis demonstrated significant increases in serum creatinine and kidney injury scores with miR-21 antagonism and pre-conditioning. No studies reported on adverse effects of miRNA therapy. Limitations also included lack of model diversity (100% rodents, 61.4% ischemia-reperfusion injury), and predominance of male sex (78.6%). Most studies had an unclear risk of bias, and the majority of miRNA-21 studies were conducted by a single team of investigators. In summary, several miRNAs target kidney function and apoptosis in pre-clinical AKI models, with data suggesting that miRNA-21 may mediate protection and kidney repair.Systematic review registration ID: CRD42019128854.

Indexed as

Acute Kidney InjuryAnimalsAntagomirsApoptosisCreatinineDrug Evaluation, PreclinicalFemaleMaleMiceMicroRNAsRatsAntagomirsCreatinineMicroRNAs

Identifiers

PMID33907298
PMCPMC8079678
OpenAlexW3157985956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.